(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 4.17% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.59%.
Bioventus's revenue in 2025 is $563,829,000.On average, 4 Wall Street analysts forecast BVS's revenue for 2025 to be $47,377,801,854, with the lowest BVS revenue forecast at $45,801,990,260, and the highest BVS revenue forecast at $49,398,879,540. On average, 4 Wall Street analysts forecast BVS's revenue for 2026 to be $50,747,092,296, with the lowest BVS revenue forecast at $48,688,771,164, and the highest BVS revenue forecast at $53,431,930,958.
In 2027, BVS is forecast to generate $53,777,881,193 in revenue, with the lowest revenue forecast at $51,722,870,589 and the highest revenue forecast at $56,398,992,180.